Summary
IDEXX Laboratories, Inc. reported solid financial results for the second quarter and first half of 2012. Total revenue increased by 5.6% and 7.8% respectively, driven by growth in the Companion Animal Group (CAG), particularly in reference laboratory services and practice management systems, as well as a notable increase in the 'Other' segment. Net income also saw a healthy increase, rising by 5.5% for the quarter and 7.4% for the first half year-over-year. The company maintained a strong balance sheet with increasing cash and cash equivalents and managed its expenses effectively, leading to improved operating income across most segments, notably in the Water segment. Despite positive revenue and profit trends, the company faced headwinds from foreign currency fluctuations, which negatively impacted reported revenue. The Livestock and Poultry Diagnostics (LPD) segment experienced a decline in revenue and gross profit, primarily due to changes in European Union testing requirements for BSE. Investors should note the ongoing FTC investigation, which the company is actively addressing by seeking to modify distributor agreements, a move expected to be effective by January 2013. The company continues to execute its share repurchase program, indicating confidence in its financial health and return of capital to shareholders.
Financial Highlights
50 data points| Revenue | $335.65M |
| Cost of Revenue | $150.96M |
| Gross Profit | $184.69M |
| R&D Expenses | $20.06M |
| Operating Income | $75.82M |
| Interest Expense | $926K |
| Net Income | $51.32M |
| EPS (Basic) | $0.47 |
| EPS (Diluted) | $0.46 |
| Shares Outstanding (Basic) | 110.16M |
| Shares Outstanding (Diluted) | 112.42M |
Key Highlights
- 1Total revenue increased by 5.6% to $335.6 million for Q2 2012 and by 7.8% to $658.3 million for the first six months of 2012.
- 2Net income attributable to IDEXX stockholders increased by 5.5% to $51.3 million for Q2 2012 and by 7.4% to $92.1 million for the first six months of 2012.
- 3The Companion Animal Group (CAG) remains the largest segment, showing a 7.1% revenue increase for Q2 2012, driven by reference laboratory services and practice management systems.
- 4The company's cash and cash equivalents increased to $201.8 million as of June 30, 2012, from $183.9 million as of December 31, 2011, indicating strong liquidity.
- 5Operating income increased by 6.3% for Q2 2012 to $75.8 million and by 9.1% for the first six months of 2012 to $136.2 million.
- 6Foreign currency exchange rates negatively impacted revenue by approximately $8.2 million in Q2 2012 and $9.8 million in the first six months of 2012.
- 7The company is actively addressing an FTC investigation into its marketing and sales practices and is seeking to modify distributor agreements to resolve concerns.